Table 2.
Univariable analysis of overall- and relapse-free survival, relapse incidence and non-relapse mortality.
| Variables | N | 2-year OS (95% CI) | p value | 2-year PFS (95% CI) | p value | 2-year CIR (95% CI) | p value | 2-year NRM (95% CI) | p value |
|---|---|---|---|---|---|---|---|---|---|
| Whole cohort | 72 | 59 (45–70) | 44 (33–58) | 25 (14–36) | 31 (20–43) | ||||
| Patient age at HCT | |||||||||
| <60 years | 45 | 66 (52–83) | 0.13 | 52 (39–70) | 0.13 | 24 (11–38) | 0.62 | 23 (10–36) | 0.11 |
| ≥60 years | 27 | 47 (30–74) | 28 (14–58) | 26 (6–46) | 45 (23–68) | ||||
| HCT-CI, score | |||||||||
| <3 | 42 | 52 (36–73) | 0.45 | 40 (26–61) | 0.49 | 22 (8–36) | 0.72 | 38 (21–55) | 0.54 |
| ≥3 | 8 | 50 (25–100) | 38 (15–92) | 25 (0–58) | 38 (0–75) | ||||
| Presence of TP53mut/del CLL | |||||||||
| Present | 29 | 86 (73–100) | 0.001 | 68 (51–90) | 0.002 | 25 (6–44) | 0.46 | 7 (0–17) | 0.001 |
| Absent | 43 | 42 (29–61) | 28 (17–47) | 25 (11–39) | 47 (31–63) | ||||
| Status with respect to chemotherapy | |||||||||
| Chemo-naive CLL | 20 | 73 (55–96) | 0.16 | 64 (44–94) | 0.02 | 14 (0–34) | 0.06 | 21 (2–41) | 0.16 |
| Chemo-exposed CLL | 51 | 52 (39–70) | 38 (26–55) | 27 (14–39) | 36 (22–50) | ||||
| Status with respect to PI | |||||||||
| No PI failed, Idela sensitive | 26 | 76 (61–95) | 0.06 | 67 (50–89) | 0.01 | 17 (1–34) | 0.13 | 16 (1–31) | 0.03 |
| ≥1 PI failed | 46 | 48 (33–68) | 30 (18–50) | 30 (15–45) | 41 (25–57) | ||||
| Chemoimmunotherapy sensitivity | |||||||||
| Not exposed | 20 | 73 (55–96) | 0.13 | 64 (44–94) | 0.03 | 14 (0–34) | 0.12 | 21 (2–41) | 0.22 |
| Sensitive disease | 18 | 60 (38–95) | 50 (32–79) | 22 (2–42) | 28 (6–49) | ||||
| poorly responsive/refractory | 33 | 47 (32–70) | 32 (19–54) | 29 (12–45) | 39 (21–58) | ||||
| Treatment failure status | |||||||||
| Failed neither PI nor CIT | 16 | 73 (54–100) | 0.003 | 64 (43–96) | <0.001 | 15 (0–37) | 0.047 | 20 (0–41) | 0.005 |
| Failed PI either or CIT | 32 | 68 (52–90) | 59 (44–79) | 19 (5–33) | 22 (7–37) | ||||
| Failed PI and CIT | 23 | 31 (16–62) | 13 (4–43) | 33 (12–54) | 54 (30–78) | ||||
| Number of lines of pretreatment | |||||||||
| ≤2 | 23 | 68 (51–91) | 0.37 | 56 (38–83) | 0.13 | 17 (0–35) | 0.16 | 27 (8–47) | 0.45 |
| ≥3 | 49 | 54 (40–72) | 38 (26–56) | 28 (15–41) | 34 (19–48) | ||||
| Remission status at alloHCT | |||||||||
| Complete/partial remission | 59 | 62 (50–78) | 0.09 | 45 (33–62) | 0.32 | 27 (14–40) | 0.57 | 28 (15–40) | 0.053 |
| Stable/progressive disease | 13 | 42 (22–82) | 35 (16–76) | 15 (0–36) | 50 (19–81) | ||||
| Donor type | |||||||||
| HLA-identical sibling | 21 | 58 (40–86) | 0.68 | 50 (32–79) | 0.38 | 19 (2–36) | 0.39 | 31 (9–53) | 0.70 |
| Alternative donor | 51 | 61 (48–76) | 41 (28–59) | 28 (14–42) | 31 (18–44) | ||||
OS overall survival, RFS relapse-free survival, RI relapse incidence, NRM non-relapse mortality, CI confidence interval, HCT hematopoietic stem cell transplantation, HCT-CI hematopoietic cell transplantation—comorbidity index, p values are based on log-rank test (OS and PFS) and Gray’s test (CIR and NRM), they compare the curves during the whole follow-up.